Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Cancer Antibody Pipeline to Bolster its Immuno-oncology Portfolio

Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Cancer Antibody Pipeline to Bolster its Immuno-oncology Portfolio

Shots: Shots:

  • Boehringer Ingelheim acquires two preclinical programs from Northern Biologic to foster its cancer immunology portfolio in exchange Northern will receive upfront, milestones and other consideration payments. The acquisition will support Boehringer’s strategy to target ‘’cold tumors with synergistic combination approaches”
  • The first program is an Ab inhibitor of Periostin, which contributes to cancer cell growth while the second program targets a key regulator of myeloid cells which plays a role in enhancing the anti-tumor T-cell function
  • The seller will retain the Northern’s name and will continue to drive certain preclinical efforts on one of the programs while Boehringer will be responsible for clinical, regulatory and commercial development of the acquired programs.  Northern will retain rights to its lead asset, MSC-1, that completed it P-I clinical studies

Click here ­to­ read full press release/ article | Ref: Boehringer Ingelheim  | Image: Square space

Related News: Boehringer Ingelheim Acquires AMAL Therapeutics for its KISIMA Immunization Platform